Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QPI-1002 for Prevention of Delayed Graft Function (ReGIFT)
NCT02610296Phase 3Completed
- Sponsor
- Quark Pharmaceuticals
- Start
- Mar 2016
- Primary completion
- Jun 2018
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 11
01
Overview
A Phase 3 trial of teprasiran in delayed graft function (DGF), sponsored by Quark Pharmaceuticals. Started Mar 2016; status: completed.
02
Drugs
teprasiran
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NCT02610296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02610296.